Cancer of Unknown Primary Site Recruiting Phase 2 Trials for Cobimetinib (DB05239)

IndicationStatusPhase
DBCOND0089665 (Cancer of Unknown Primary Site)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03498521A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteTreatment